Press Releases Pfizer Inc.

Stocks

PFE

US7170811035

Pharmaceuticals

Market Closed - NYSE Other stock markets 21:02:41 12/06/2026 BST			5-day change	1st Jan Change
26.21 ^USD	+0.15%		+0.65%	+5.26%

06-12	Drugmakers will not be exempt from cost cuts, says German health minister	RE
06-12	After Euphoria, a Traffic Jam on the Multi-Billion Dollar Kilo-Highway

Press Releases

06-08	U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need	BU
06-06	Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide	BU
06-01	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
05-31	Pfizer : BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	PU
05-31	Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	BU
05-30	TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer	BU
05-29	Pfizer : European Commission Authorizes Update to Pediatric Use of Pfizer and BioNTech COVID 19 Vaccine	PU
05-29	Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer	BU
05-29	Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines	BU
05-27	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
05-20	Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results	BU
05-13	European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors	BU
05-12	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)	AQ
05-06	Pfizer : First Quarter 2026 Transcript	PU
05-05	Pfizer : Quarterly Corporate Performance - First Quarter 2026 Press Release	PU
05-05	Pfizer : Quarterly Corporate Performance - First Quarter 2026 Presentation	PU
05-05	Pfizer : Quarterly Corporate Performance - First Quarter 2026 Prepared Remarks	PU
05-05	Pfizer : First Quarter 2026 Earnings Teleconference	PU
05-05	Pfizer: Q1 Earnings Snapshot	AQ
05-05	Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance	BU
04-29	Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma	BU
04-28	Pfizer Reaches Three Settlement Agreements for VYNDAMAX	BU
04-23	Pfizer : Announces 2026 Shareholder Meeting Preliminary ResultsCorporateFinance	PU
04-22	Pfizer Declares Second-Quarter 2026 Dividend	BU
04-21	Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026	BU